GeneReach Biotechnology Corp. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was TWD 48.2 million compared to TWD 106.65 million a year ago. Revenue was TWD 48.19 million compared to TWD 105.82 million a year ago. Net loss was TWD 24.73 million compared to net income of TWD 36.92 million a year ago. Basic loss per share from continuing operations was TWD 0.43 compared to basic earnings per share from continuing operations of TWD 0.64 a year ago. Diluted loss per share from continuing operations was TWD 0.43 compared to diluted earnings per share from continuing operations of TWD 0.64 a year ago.
For the nine months, sales was TWD 170.8 million compared to TWD 665.81 million a year ago. Revenue was TWD 170.64 million compared to TWD 664.75 million a year ago. Net loss was TWD 108.06 million compared to net income of TWD 273.9 million a year ago. Basic loss per share from continuing operations was TWD 1.88 compared to basic earnings per share from continuing operations of TWD 4.77 a year ago. Diluted loss per share from continuing operations was TWD 1.88 compared to diluted earnings per share from continuing operations of TWD 4.64 a year ago.